Literature DB >> 19917855

Oropharyngeal cancer, human papilloma virus, and clinical trials.

Danny Rischin.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19917855     DOI： 10.1200/JCO.2009.24.9045

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma.

Authors:  Gustavo Jacob Lourenço; Erika Furquim Soledade Neves Silva; José Augusto Rinck-Junior; Carlos Takahiro Chone; Carmen Silvia Passos Lima
Journal:  Tumour Biol       Date:  2011-08-26

2.  Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.

Authors:  Ji Won Kim; Jungsu S Oh; Jong-Lyel Roh; Jae Seung Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-12       Impact factor: 9.236

3.  Adenocarcinoma not otherwise specified on dorsum of tongue: case report and literature review.

Authors:  B A Market Velker; A V Louie; V M Velker; K F Kwan; J H Franklin; V M Venkatesan
Journal:  Curr Oncol       Date:  2012-10       Impact factor: 3.677

Review 4.  The molecular landscape of head and neck cancer.

Authors:  C René Leemans; Peter J F Snijders; Ruud H Brakenhoff
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

5.  The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan.

Authors:  Paul B Romesser; Remy Lim; Daniel E Spratt; Jeremy Setton; Nadeem Riaz; Benjamin Lok; Shyam Rao; Eric J Sherman; Heiko Schöder; Nancy Y Lee
Journal:  Oral Oncol       Date:  2014-07-17       Impact factor: 5.337

6.  Definitive radiochemotherapy or initial surgery for oropharyngeal cancer : To what extent can p16 expression be used in the decision process?

Authors:  Anouchka Modesto; Thibaut Galissier; Amélie Lusque; Jean-Pierre Delord; Emmanuelle Uro-Coste; Jérôme Sarini; Frédéric Mouchet; Raphaël Lopez; Anne Laprie; Pierre Graff; Sébastien Vergez; Michel Rives
Journal:  Strahlenther Onkol       Date:  2019-03-15       Impact factor: 3.621

7.  Association between polymorphisms in genes related to DNA base-excision repair with risk and prognosis of oropharyngeal squamous cell carcinoma.

Authors:  Ericka Francislaine Dias Costa; Erika Stocco Santos; Vitor Teixeira Liutti; Frederico Leal; Vivian Castro Antunes Santos; José Augusto Rinck-Junior; Fernanda Viviane Mariano; Cláudia Malheiros Coutinho-Camillo; Albina Altemani; Carmen Silvia Passos Lima; Gustavo Jacob Lourenço
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-02       Impact factor: 4.553

8.  The clinical impact of p16 status in fine-needle aspirates of cervical lymph node metastasis of head and neck squamous cell carcinomas.

Authors:  Jens Jakscha; Inti Zlobec; Claudio Storck; Ellen C Obermann; Luigi Tornillo; Luigi M Terracciano; Claude A Fischer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-16       Impact factor: 2.503

9.  Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.

Authors:  Y Nakaya; K Shide; T Niwa; J Homan; S Sugahara; T Horio; K Kuramoto; T Kotera; H Shibayama; K Hori; H Naito; K Shimoda
Journal:  Blood Cancer J       Date:  2011-07-22       Impact factor: 11.037

10.  CASP8 (rs3834129) and CASP3 (rs4647601) polymorphisms in oropharynx cancer risk, tumor cell differentiation, and prognosis in a cohort of the Brazilian population.

Authors:  Gabriela Arielo Tortorelli; Caroline Torricelli; Juliana Carron; Ericka Francislaine Dias Costa; Leisa Lopes-Aguiar; Bruna Fernandes Carvalho; José Augusto Rinck-Junior; Fernanda Viviane Mariano; Albina Messias Almeida Milani Altemani; Carmen Silvia Passos Lima; Gustavo Jacob Lourenço
Journal:  Mol Biol Rep       Date:  2019-10-05       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.